Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib and Fulvestrant in Advanced HR+ Breast Cancer
NCT02219789Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in breast cancer, sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Dec 2014; status: completed.
02
Drugs
alisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02219789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219789.